SG11201406142XA - Compositions and methods for the prevention and treatment of mast cell-induced vascular leakage - Google Patents
Compositions and methods for the prevention and treatment of mast cell-induced vascular leakageInfo
- Publication number
- SG11201406142XA SG11201406142XA SG11201406142XA SG11201406142XA SG11201406142XA SG 11201406142X A SG11201406142X A SG 11201406142XA SG 11201406142X A SG11201406142X A SG 11201406142XA SG 11201406142X A SG11201406142X A SG 11201406142XA SG 11201406142X A SG11201406142X A SG 11201406142XA
- Authority
- SG
- Singapore
- Prior art keywords
- prevention
- compositions
- treatment
- methods
- mast cell
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
- A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/4535—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a heterocyclic ring having sulfur as a ring hetero atom, e.g. pizotifen
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/55—Protease inhibitors
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/573—Immunoassay; Biospecific binding assay; Materials therefor for enzymes or isoenzymes
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/005—Assays involving biological materials from specific organisms or of a specific nature from viruses
- G01N2333/08—RNA viruses
- G01N2333/175—Bunyaviridae, e.g. California encephalitis virus, Rift valley fever virus, Hantaan virus
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/005—Assays involving biological materials from specific organisms or of a specific nature from viruses
- G01N2333/08—RNA viruses
- G01N2333/18—Togaviridae; Flaviviridae
- G01N2333/183—Flaviviridae, e.g. pestivirus, mucosal disease virus, bovine viral diarrhoea virus, classical swine fever virus (hog cholera virus) or border disease virus
- G01N2333/185—Flaviviruses or Group B arboviruses, e.g. yellow fever virus, japanese encephalitis, tick-borne encephalitis, dengue
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/475—Assays involving growth factors
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/52—Assays involving cytokines
- G01N2333/54—Interleukins [IL]
- G01N2333/5412—IL-6
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/90—Enzymes; Proenzymes
- G01N2333/914—Hydrolases (3)
- G01N2333/948—Hydrolases (3) acting on peptide bonds (3.4)
- G01N2333/95—Proteinases, i.e. endopeptidases (3.4.21-3.4.99)
- G01N2333/964—Proteinases, i.e. endopeptidases (3.4.21-3.4.99) derived from animal tissue
- G01N2333/96425—Proteinases, i.e. endopeptidases (3.4.21-3.4.99) derived from animal tissue from mammals
- G01N2333/96427—Proteinases, i.e. endopeptidases (3.4.21-3.4.99) derived from animal tissue from mammals in general
- G01N2333/9643—Proteinases, i.e. endopeptidases (3.4.21-3.4.99) derived from animal tissue from mammals in general with EC number
- G01N2333/96433—Serine endopeptidases (3.4.21)
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/26—Infectious diseases, e.g. generalised sepsis
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/50—Determining the risk of developing a disease
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201261616062P | 2012-03-27 | 2012-03-27 | |
PCT/US2013/032553 WO2013148366A1 (en) | 2012-03-27 | 2013-03-15 | Compositions and methods for the prevention and treatment of mast cell-induced vascular leakage |
Publications (1)
Publication Number | Publication Date |
---|---|
SG11201406142XA true SG11201406142XA (en) | 2014-10-30 |
Family
ID=49261101
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
SG11201406142XA SG11201406142XA (en) | 2012-03-27 | 2013-03-15 | Compositions and methods for the prevention and treatment of mast cell-induced vascular leakage |
Country Status (6)
Country | Link |
---|---|
US (2) | US9730921B2 (pt) |
AU (1) | AU2013240220B2 (pt) |
BR (1) | BR112014024287A2 (pt) |
IN (1) | IN2014KN02323A (pt) |
SG (1) | SG11201406142XA (pt) |
WO (1) | WO2013148366A1 (pt) |
Families Citing this family (30)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US9925282B2 (en) | 2009-01-29 | 2018-03-27 | The General Hospital Corporation | Cromolyn derivatives and related methods of imaging and treatment |
US9301999B2 (en) | 2009-09-28 | 2016-04-05 | Duke University | Peptide, adjuvants, vaccines, and methods of use |
AU2013240220B2 (en) | 2012-03-27 | 2017-07-20 | Duke University | Compositions and methods for the prevention and treatment of mast cell-induced vascular leakage |
CN105263579B (zh) | 2013-03-13 | 2020-01-10 | 炎症反应研究公司 | 左西替利嗪和孟鲁司特在治疗血管炎中的用途 |
MX370953B (es) | 2013-03-13 | 2020-01-10 | Inflammatory Response Res Inc | Uso de levocetirizina y montelukast en el tratamiento de trastornos autoinmunes. |
CN105517631A (zh) | 2013-03-13 | 2016-04-20 | 炎症反应研究公司 | 左西替利嗪和孟鲁司特在治疗创伤性损伤中的用途 |
CN103630645B (zh) * | 2013-11-27 | 2016-08-17 | 中国检验检疫科学研究院 | 一种测定化妆品中苯海拉明含量的液相色谱-串联质谱法 |
BR112016018062B1 (pt) | 2014-02-07 | 2022-11-16 | Exithera Pharmaceuticals Inc | Compostos terapêuticos, composição farmacêutica e usos |
EP3104853B1 (en) | 2014-02-10 | 2019-10-02 | Respivant Sciences GmbH | Mast cell stabilizers treatment for systemic disorders |
SI3104854T1 (sl) | 2014-02-10 | 2020-09-30 | Respivant Sciences Gmbh | Stabilizatorji mastocitov za zdravljenje pljučnih bolezni |
CN103735546A (zh) * | 2014-02-11 | 2014-04-23 | 中国人民解放军军事医学科学院放射与辐射医学研究所 | 4-氧代-8-[4-(4-苯基丁氧基)苯甲酰氨基]-2-四氮杂茂-4h-1-苯并吡喃-半水合物的新用途 |
DE102014111892A1 (de) * | 2014-08-20 | 2016-02-25 | Eberhard Karls Universität Tübingen Medizinische Fakultät | Prophylaxe und Behandlung einer Infektion mit dem Hantavirus |
JP2017526728A (ja) | 2014-09-15 | 2017-09-14 | インフラマトリー・レスポンス・リサーチ・インコーポレイテッド | 炎症介在性状態の治療におけるレボセチリジン及びモンテルカスト |
WO2016102941A1 (en) | 2014-12-22 | 2016-06-30 | Rspr Pharma Ab | New combination of pemirolast and montelukast |
US10265296B2 (en) | 2015-08-07 | 2019-04-23 | Respivant Sciences Gmbh | Methods for the treatment of systemic disorders treatable with mast cell stabilizers, including mast cell related disorders |
EP3331522A1 (en) | 2015-08-07 | 2018-06-13 | Patara Pharma LLC | Methods for the treatment of mast cell related disorders with mast cell stabilizers |
WO2017096049A1 (en) | 2015-12-03 | 2017-06-08 | The University Of North Carolina At Pembroke | Materials for cathepsin b enhancement and methods of use |
EP3487875A4 (en) * | 2016-07-19 | 2020-02-12 | Arete Discoveries, Inc. | BIOMARKERS FOR THE DETECTION AND TREATMENT OF DISORDERS ASSOCIATED WITH THE ACTIVITY OF MASTOCYTES |
EP3506893A4 (en) | 2016-08-31 | 2020-01-22 | Respivant Sciences GmbH | CROMOLYNE COMPOSITIONS FOR THE TREATMENT OF CHRONIC COUGH DUE TO IDIOPATHIC PULMONARY FIBROSIS |
KR20190044647A (ko) | 2016-08-31 | 2019-04-30 | 더 제너럴 하스피탈 코포레이션 | 신경변성 질환과 관련된 신경-염증에서 대식세포/미세아교세포 |
WO2018067341A1 (en) | 2016-10-07 | 2018-04-12 | Patara Pharma, LLC | Cromolyn compositions for treatment of pulmonary fibrosis |
CN106511346A (zh) * | 2016-12-08 | 2017-03-22 | 上海市公共卫生临床中心 | 一种可用于抑制寨卡病毒感染的小分子药物及其应用 |
US11872210B2 (en) | 2017-01-30 | 2024-01-16 | Western New England University | Thiol isomerases inhibitors and use thereof |
CN108872405B (zh) * | 2017-05-11 | 2021-06-01 | 武汉先路医药科技股份有限公司 | 一种洛度沙胺氨丁三醇有关物质的hplc分析检测方法 |
CN111886025A (zh) * | 2017-11-01 | 2020-11-03 | 新加坡国立大学 | 血清素能药物治疗病毒诱发的血小板减少症的用途 |
WO2019156929A1 (en) | 2018-02-07 | 2019-08-15 | eXIthera Pharmaceuticals Inc. | Therapeutic compounds and compositions |
KR102269663B1 (ko) * | 2018-04-27 | 2021-06-28 | 주식회사 레모넥스 | 플라비바이러스 감염증의 예방 또는 치료용 약학적 조성물 |
CN113038945A (zh) * | 2018-09-05 | 2021-06-25 | 通用医疗公司 | 细胞因子释放综合征的治疗方法 |
MX2018011699A (es) | 2018-09-26 | 2019-07-24 | Federico Amezcua Amezcua | Composicion farmaceutica sinergica de un antagonista de los receptores de leucotrienos y un agonista inverso de la histamina h1. |
CN110237074B (zh) * | 2019-07-25 | 2021-09-21 | 中国科学院武汉病毒研究所 | 贝尼地平在制备预防和/或治疗布尼亚病毒感染性疾病药物中的应用 |
Family Cites Families (17)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CA2061862A1 (en) | 1991-03-04 | 1992-09-05 | Jonathan Duvick | Natural and synthetic proteins with inhibitory activity towards pathogenic microorganisms |
AU2514592A (en) | 1991-08-21 | 1993-03-16 | Board Of Regents, The University Of Texas System | Methods and compositions for modulating g protein action |
US6887470B1 (en) | 1999-09-10 | 2005-05-03 | Conjuchem, Inc. | Protection of endogenous therapeutic peptides from peptidase activity through conjugation to blood components |
US6849714B1 (en) | 1999-05-17 | 2005-02-01 | Conjuchem, Inc. | Protection of endogenous therapeutic peptides from peptidase activity through conjugation to blood components |
IL140473A0 (en) | 2000-12-21 | 2002-02-10 | Allergene Ltd | Anti-allergic complex molecules |
US20020041898A1 (en) | 2000-01-05 | 2002-04-11 | Unger Evan C. | Novel targeted delivery systems for bioactive agents |
DE10055375A1 (de) * | 2000-11-08 | 2002-05-23 | Infineon Technologies Ag | Auswerteschaltung für Wechselspannungsimpulse |
WO2004071531A1 (en) * | 2003-02-13 | 2004-08-26 | Licentia Oy | Use of a mast cell activation or degranulation blocking agent in the manufacture of a medicament for the treatment of cerebral ischemia |
WO2004071532A1 (en) | 2003-02-13 | 2004-08-26 | Licentia Oy | Use of a mast cell activation or degranulation blocking agent in the manufacture of a medicament for the treatment of a patient subjected to thrombolyses |
US8076059B2 (en) | 2003-04-16 | 2011-12-13 | Duke University | Adjuvant capable of specifically activating the adaptive immune response |
GB0427267D0 (en) | 2004-12-13 | 2005-01-12 | Maria Teresa De Magistris | Peptide adjuvants |
WO2006091610A2 (en) * | 2005-02-23 | 2006-08-31 | The Brigham And Women's Hospital, Inc. | Inhibitors of enveloped virus infectivity |
WO2009043464A2 (en) | 2007-09-11 | 2009-04-09 | Mondobiotech Laboratories Ag | Astressin and beta- endorphin for use as therapeutic agents |
US8080518B2 (en) | 2007-12-05 | 2011-12-20 | Arbor Vita Corporation | Co-administration of an agent linked to an internalization peptide with an anti-inflammatory |
US9301999B2 (en) | 2009-09-28 | 2016-04-05 | Duke University | Peptide, adjuvants, vaccines, and methods of use |
BR112012025568A2 (pt) * | 2010-04-07 | 2017-03-28 | Abbvie Inc | proteínas de ligação ao tnf-<244>. |
AU2013240220B2 (en) | 2012-03-27 | 2017-07-20 | Duke University | Compositions and methods for the prevention and treatment of mast cell-induced vascular leakage |
-
2013
- 2013-03-15 AU AU2013240220A patent/AU2013240220B2/en active Active
- 2013-03-15 US US14/388,140 patent/US9730921B2/en active Active
- 2013-03-15 BR BR112014024287-9A patent/BR112014024287A2/pt not_active IP Right Cessation
- 2013-03-15 SG SG11201406142XA patent/SG11201406142XA/en unknown
- 2013-03-15 WO PCT/US2013/032553 patent/WO2013148366A1/en active Application Filing
-
2014
- 2014-10-21 IN IN2323KON2014 patent/IN2014KN02323A/en unknown
-
2017
- 2017-07-12 US US15/648,119 patent/US10668059B2/en active Active
Also Published As
Publication number | Publication date |
---|---|
US20150038530A1 (en) | 2015-02-05 |
US20170368050A1 (en) | 2017-12-28 |
IN2014KN02323A (pt) | 2015-05-01 |
US9730921B2 (en) | 2017-08-15 |
AU2013240220A1 (en) | 2014-10-16 |
WO2013148366A1 (en) | 2013-10-03 |
AU2013240220B2 (en) | 2017-07-20 |
BR112014024287A2 (pt) | 2018-05-08 |
US10668059B2 (en) | 2020-06-02 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
SG11201406142XA (en) | Compositions and methods for the prevention and treatment of mast cell-induced vascular leakage | |
IL266582A (en) | Compositions and methods for the treatment of hemoglobinopathies | |
HK1210957A1 (en) | Effluz inhibitor compositions and methods of treatment using the same | |
HK1209788A1 (en) | Methods and compositions for the treatment of lysosomal storage diseases | |
HK1204461A1 (en) | Compositions and methods of use of phorbol esters for the treatment of stroke | |
EP2832366A4 (en) | PHARMACEUTICAL COMPOSITION FOR THE TREATMENT AND / OR PREVENTION OF CANCER OF BILARY VESICLE | |
EP2847152A4 (en) | COMPOSITIONS AND METHOD FOR THE TREATMENT OF METABOLIC SYNDROME | |
IL225471A0 (en) | Preparations and methods for the prevention and treatment of cancer | |
IL238177A0 (en) | Methods and preparations for the treatment of cancer | |
EP2825242A4 (en) | DEVICES AND METHOD FOR THE TREATMENT OF VASCULAR DEFECTS | |
ZA201408056B (en) | Compositions and methods for the treatment of mucositis | |
EP2558085A4 (en) | COMPOSITIONS AND METHODS FOR THE PREVENTION AND TREATMENT OF CANCER | |
EP2938289A4 (en) | DEVICES AND METHODS FOR TREATING VASCULAR DEFECTS | |
HK1201045A1 (en) | Compositions and methods for the diagnosis and treatment of tumor | |
EP2828241A4 (en) | COMPOSITIONS AND METHOD FOR INHIBITING CATHEPSINES | |
GB201217296D0 (en) | Method of treatment and/or prevention | |
HK1211221A1 (en) | Formulations for the treatment and prevention of obesity | |
ZA201408055B (en) | Compositions and methods for the treatment of local pain | |
ZA201408062B (en) | Compositions and methods for the treatment of multiple sclerosis | |
IL238602A0 (en) | Preparations and methods for the treatment of ectodermal dysplasia | |
HK1216721A1 (zh) | 治療肝臟疾病或病狀的用途和方法 | |
PL3082845T3 (pl) | Sposoby i kompozycje do leczenia neuropatii obwodowych | |
ZA201408058B (en) | Compositions and methods for the treatment of epilepsy | |
ZA201408065B (en) | Compositions and methods for the treatment of diabetes | |
ZA201408053B (en) | Compositions and methods for the treatment of metabolic syndrome |